Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade
about
Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureTo Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic VirusesNovel Drugs and Combination Therapies for the Treatment of Metastatic MelanomaHuman Cancer Immunotherapy with PD-1/PD-L1 BlockadeConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsCombining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyClinical trials of dendritic cell-based cancer vaccines in hematologic malignanciesAdoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookThe role of regulatory T cells in cancer immunologyWhat future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?Science gone translational: the OX40 agonist storyEfficacy of β-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal PneumoniaBlockade of the B7-H1/PD-1 pathway for cancer immunotherapyThe receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functionsPD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaCurrent status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.Targeted immunotherapy for non-small cell lung cancer.IgE-based immunotherapy of cancer: challenges and chances.Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.OX40 is a potent immune-stimulating target in late-stage cancer patients.Combinations of immunotherapy and radiation in cancer therapy.CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerationsNovel immune checkpoint blocker approved for the treatment of advanced melanomaCD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysisExpression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma.The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cellsVictory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.Therapeutic cancer vaccines: current status and moving forward.Immunotherapy treatments for small-cell lung cancer: past, present and future.Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models.Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms.Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.The role of checkpoints in the treatment of GBMOligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2.Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.Parapharyngeal liposarcoma: a case report.Induction of IL-25 secretion from tumour-associated fibroblasts suppresses mammary tumour metastasis.Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma.
P2860
Q26746934-8C8D2DDF-215E-4F40-B1F8-8D5D349B8F46Q26767212-7FBA10CE-236C-4B95-8A5E-55097382628EQ26772015-367D5E8C-0255-429D-8B59-A3B6B2F3CF18Q26786108-0CAA292C-D853-4BD8-BC93-289A0ECD5607Q26830569-AE508AE4-4744-43DB-89A4-6947800E9C09Q26851608-EF3459CC-FF44-435A-8438-08F61E40F6AAQ26864603-D0400261-EB44-455A-90AA-4E74F7D4A863Q27004178-4013F92D-DC0E-4A95-9979-630B81B210FBQ27006663-CB0493D5-0CE8-410E-81E3-C2E60B7E9966Q27012886-92C2BBE8-6E8C-4317-B7FB-58A1D9DBDC83Q27022436-D2299597-04FF-4B4F-A4A3-EA7F4FDCE7CEQ28390204-D41E1499-966A-40D0-95B5-1204408F2831Q28394869-BAB2BCBF-3C50-439C-B26E-7651B2BD7B38Q28589215-DE6FA387-9C76-4FA4-B25D-E03FF36DFB9FQ29620878-8EEA4D26-135C-407A-AFB1-CD27C18F089BQ30412300-AB0FA2FB-8144-42A2-949A-4497358DAC4AQ33585089-52344CB4-35D1-4CAC-9F9D-A5A306715A55Q33619979-BE3AE501-FB1D-458E-9C04-43F762A45C19Q34321844-AB9833F6-0542-45BC-A143-04BE857B8A5AQ34381674-E546294E-3B93-4ACD-B982-6D4BDE02BB41Q34582640-A255DFAD-73B9-4569-8C56-807C593B1969Q34667662-0A6AA773-A9F0-4D45-809C-01468DE92EFDQ34936394-FAF28635-6FCE-46AE-B200-D9B47ACAB27FQ34976095-2383D119-E47D-444B-AC6A-F70C9FE6C6E1Q35290679-43F1BEF5-58CE-4DD4-80A1-37483ACF2EF9Q35329825-BA78A7B6-1F77-446A-BE3D-7BD885BDBF0AQ35743681-FFA6AF8A-63EB-45B3-98AF-582867D5D570Q35799695-6687F1C7-0C7A-4E70-8839-FDFF488DA72BQ35894347-C685E18B-A8EE-4238-88F4-6C1B2FFAFC8DQ35904003-A39F1C9C-F95D-4BF4-98F2-78FFAB82BB60Q36021225-AD87BEAF-05B8-482D-B61C-748A10A23C87Q36060324-9962805E-5419-434B-93BC-9B18CCDA5CD4Q36067524-B144C7F8-FD1B-4B44-95B6-F13C3BD1C131Q36557537-5F6B59B6-93D7-4CF6-9C05-147FABA79198Q36571197-5930691D-B477-44FC-867E-34181C814D8CQ36586115-3BB725E1-9093-4E03-9952-A51F90EBA5E8Q36653524-7FC2DE68-6E65-49A3-99C3-6E3F8F435554Q36690223-6F68AD8B-7A53-4C8A-8BA6-9571246B41B3Q36815168-F70C2EA1-3EA8-4D82-B902-8274D85F1B97Q36879912-1C2E6B5E-F2EA-4A24-A639-82A2BA603F41
P2860
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Immune checkpoint proteins: a ...... ound: CTLA-4 and PD-1 blockade
@ast
Immune checkpoint proteins: a ...... ound: CTLA-4 and PD-1 blockade
@en
Immune checkpoint proteins: a ...... ound: CTLA-4 and PD-1 blockade
@nl
type
label
Immune checkpoint proteins: a ...... ound: CTLA-4 and PD-1 blockade
@ast
Immune checkpoint proteins: a ...... ound: CTLA-4 and PD-1 blockade
@en
Immune checkpoint proteins: a ...... ound: CTLA-4 and PD-1 blockade
@nl
prefLabel
Immune checkpoint proteins: a ...... ound: CTLA-4 and PD-1 blockade
@ast
Immune checkpoint proteins: a ...... ound: CTLA-4 and PD-1 blockade
@en
Immune checkpoint proteins: a ...... ound: CTLA-4 and PD-1 blockade
@nl
P3181
P1433
P1476
Immune checkpoint proteins: a ...... ound: CTLA-4 and PD-1 blockade
@en
P2093
Jeffrey Weber
P3181
P356
10.1053/J.SEMINONCOL.2010.09.005
P407
P577
2010-10-01T00:00:00Z